Drug Research
Chi-Med Announces Surufatinib Granted FDA Orphan Drug Designation for Pancreatic Neuroendocrine Tumors
Hutchison China MediTech Limited announces that the U.S. FDA has granted Orphan Drug designation to surufatinib for the treatment of pancreatic neuroendocrine tumors.
“NET is an...
Drug Research
Bayer and Dewpoint Therapeutics partner to research new treatments for cardiovascular and gynecological diseases
Bayer and Dewpoint Therapeutics, a biotechnology company with sites in Boston and Dresden, Germany, announced an option, research and license agreement worth up to USD...
Drug Research
DuPont Reveals Enhanced Application and Innovation Center, Increased Production Capacity at CPhI India
DuPont Nutrition & Biosciences has consistently advanced its customers forward by ensuring global access to indispensable ingredients and unmatched expertise. At CPhI India, the company...
Drug Research
Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases
US-based Dicerna Pharmaceuticals and Novo Nordisk have signed a deal worth up to around $607m to discover and develop drugs for liver-related cardio-metabolic diseases.
In this...
Drug Research
WuXi STA Forms Strategic Partnership with Impact Therapeutics
STA Pharmaceutical Co Ltd – a subsidiary of WuXi AppTec – and Impact Therapeutics, a biotech focused on innovative drug discovery and development in anti-cancer...
Drug Research
Lonza Partners with Cryoport and Strengthens its Vein-to-vein Delivery Network in Cell & Gene Therapy
Lonza and Cryoport, Inc announced their partnership in the cell and gene therapy field and across Lonza's 'vein-to-vein' delivery network. As a part of this...
Drug Research
A2 Biotherapeutics emerges from Stealth Mode to develop tumour cell therapeutics
A2 Biotherapeutics, a biotechnology company developing innovative cell therapies for cancer patients, announced its official launch. The company, founded in 2018 by veteran biotechnology leaders,...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.